신테카바이오 is an AI-driven drug discovery company that leverages genomic big data to develop novel therapeutics and collaborative drug-development programs. The company advances both its own pipeline and joint projects with pharmaceutical partners; it received an immuno-oncology candidate via technology transfer from CJ Healthcare in March and signed an MOU in May with Cellid and SCM Life Science to expand joint R&D. Proceeds from the recent financing will be used to accelerate internal pipeline development and to expand R&D and headcount for collaboration projects. The company has an established history of partnerships with firms such as CJ Healthcare and JW중외제약. Financially, 신테카바이오 completed a ₩20 billion Series C and previously raised ₩6 billion in a 2016 Series A and ₩12 billion in a 2018 Series B. It is also preparing for an IPO and has been working with KB Securities as lead underwriter while implementing governance updates and auditor appointments.

Total raised

$17M

Funding rounds

1

Latest round

Series C

Latest activity

Jul 2019